Clark Estates Inc. NY Buys New Position in Indivior PLC (NASDAQ:INDV)

Clark Estates Inc. NY acquired a new position in Indivior PLC (NASDAQ:INDV) in the 3rd quarter, Holdings Channel.com reports. The firm acquired 254,100 shares of the company’s stock, valued at approximately $2,477,000.

Several other institutional investors have also recently made changes to their positions in INDV. AlphaCentric Advisors LLC bought a new position in shares of Indivior in the third quarter worth approximately $2,364,000. Susquehanna International Group Ltd. bought a new stake in shares of Indivior during the second quarter valued at approximately $3,224,000. Millennium Management LLC raised its position in shares of Indivior by 48.1% during the second quarter. Millennium Management LLC now owns 493,313 shares of the company’s stock valued at $7,952,000 after buying an additional 160,282 shares during the last quarter. Mediolanum International Funds Ltd purchased a new position in shares of Indivior in the third quarter worth $1,240,000. Finally, VELA Investment Management LLC boosted its position in shares of Indivior by 722.9% during the third quarter. VELA Investment Management LLC now owns 123,435 shares of the company’s stock worth $1,212,000 after acquiring an additional 108,435 shares during the last quarter. Institutional investors own 60.33% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on INDV shares. Craig Hallum cut their target price on shares of Indivior from $20.00 to $16.00 and set a “buy” rating for the company in a report on Friday, October 11th. Piper Sandler reissued an “overweight” rating and set a $16.00 target price (up previously from $15.00) on shares of Indivior in a research report on Friday, October 25th.

Indivior Trading Up 2.7 %

Shares of Indivior stock opened at $11.18 on Wednesday. Indivior PLC has a 52 week low of $7.33 and a 52 week high of $23.22. The stock’s fifty day moving average is $9.53 and its two-hundred day moving average is $12.42. The company has a quick ratio of 0.65, a current ratio of 0.83 and a debt-to-equity ratio of 23.50.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Thursday, October 24th. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.39 by $0.15. The company had revenue of $307.00 million for the quarter, compared to the consensus estimate of $302.25 million. Indivior had a negative net margin of 0.17% and a negative return on equity of 351.08%. Sell-side analysts predict that Indivior PLC will post 1.66 earnings per share for the current fiscal year.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.